Tests BMS-986488 alone or combined in adults with advanced cancers
Tests BMS-986488, alone or with other drugs, in adults with advanced cancers.
Plain-language title generated from the registry record
Registry title: A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
Key facts
- Where
- Montreal, Québec, and Vancouver, CanadaSee the 3 sites
- Phase
- Phase 1
Where in Canada
- MontrealMontreal, CanadaNot yet recruiting
- Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-JésusQuébec, CanadaTaking people
- BC Cancer - VancouverVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06764771
- Record updated
- 29 July 2026
- Original description
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.Read full original descriptionShow less
A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
Inclusion: Participant must be ≥ 18 years of age; Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:; Part 1A: clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC); Parts 2A, 1D, 2D: ccRCC; Part 1B: solid tumors with KRAS G12C mutation; Part 2B: NSCLC with KRAS G12C mutation; Parts 1C, 2C: colorectal cancer (CRC) with KRAS G12C mutation; Participants must have an Eastern Cooperative Oncology Groups (ECOG) Performance Status of 0 or 1; Participants must have measurable disease per RECIST v1.1.
Exclusion: History of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN); Impaired cardiac function or clinically significant cardiac disease; For Parts 1B, 1C, 2B, 2C only (combination with adagrasib):; History of pneumonitis or interstitial lung disease (ILD); Untreated central nervous system (CNS) metastases; Leptomeningeal metastasis (carcinomatous meningitis); Other protocol-defined inclusion/exclusion criteria apply.